ADALTA LIMITED - News & Media

Market Cap $11.51M Add to my watchlist

AdAlta Limited is an Australia-based clinical-stage biotechnology company. The Company... AdAlta Limited is an Australia-based clinical-stage biotechnology company. The Company uses its i-body platform to discover and develop protein therapeutics addressing drug targets that are challenging for other technologies. The Company's first-in-class lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. It is also engaged in developing i-body enabled Chimeric antigen receptor T cell (CAR-T) cells. It co-develops i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

No News & Media currently available.

(20min delay)
Last 1.8¢		Change 0.000(0.00%)		Mkt cap ! $11.51M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
3	718710	1.7¢

Sellers (Offers)

Price($)	Vol.	No.
1.9¢	560699	4

View Market Depth

No.	Vol.	Price($)
1	39404	0.019
5	656053	0.018
1	1000000	0.017
2	312561	0.016
1	90999	0.011

Price($)	Vol.	No.
0.020	251436	1
0.021	555555	1
0.022	810000	2
0.023	92643	2
0.024	425050	3

Last trade - 16.13pm 15/11/2024 (20 minute delay)

1AD (ASX) Chart

Day chart unavailable